Home
Mercati
Grafici & Idee
Algo
Notizie
Store
Broker
Scarica
Calendario Economico
Segnali di Trading
Terminale Web
Digita
/
per cercare: @user, $symbol
Cerca
Accedi
Crea un account
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRTC
#5778
PureTech Health plc American Depositary Shares
16.7
7
+0.72%
Settore:
Base:
Valuta di Profitto:
Intervallo Giornaliero
Intervallo Annuale
Variazione giornaliera
+0.72%
Variazione Mensile
-11.69%
Variazione di 6 mesi
-4.17%
Variazione Annuale
-5.79%
Chiusura Precedente
16.6
5
Open
17.0
0
Bid
Ask
Low
16.7
7
High
17.0
0
Volume
2
Mercati
Mercato Azionario Statunitense
Salute
PRTC
Open full chart
Financials
Overview
Estratto Conto
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q4, 24
Total assets
—
Total liabilities
—
Total equity
—
Total liabilities & shareholders' equities
—
Total debt
—
Net debt
—
PureTech Health plc - American Depositary Shares
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
Notizie
Deupirfenidona recibe estatus de medicamento huérfano para enfermedad pulmonar rara
Deupirfenidona recibe estatus de fármaco huérfano para enfermedad pulmonar rara
Deupirfenidone receives orphan drug status for rare lung disease
La deupirfenidona de PureTech recibe estatus de fármaco huérfano de la FDA y la UE para FPI
Deupirfenidona de PureTech recibe estatus huérfano de FDA y UE para FPI
PureTech’s deupirfenidone receives FDA and EU orphan drug status for IPF
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CEO de PureTech presentará en la Conferencia de Salud de J.P. Morgan
PureTech CEO to present at J.P. Morgan Healthcare Conference
PureTech Health nombra a Robert Lyne como CEO permanente
PureTech Health nombra a Robert Lyne como CEO permanente
PureTech Health appoints Robert Lyne as permanent CEO